Baxter Healthcare Sa

Mount Sinai School of Medicine

Other

Icahn School of Medicine at Mount Sinai

Blue Sky Vaccines Gmbh

Avir Green Hills Biotechnology Research Development Trade Ag

Vivaldi Biosciences Inc.

Baxalta Gmbh

Nanotherapeutics, Inc.

Polymun Scientific Immunbiologische Forschung Gmbh

Bia Separations D.o.o.

Bluesky Immunotherapies Gmbh

Polynum Scientific Immunbiologische Forschung Gmbh

Avir Green Hills Biotechnology Research Devlopment Trade Ag

Thomas Muster

Peter M Palese

Markus Wolschek

Adolfo Garcia-Sastre

Hermann W Katinger

Franz J Steindl

Andrej Egorov

Martin Purtscher

Alexandra Trkola

Gottfried Himmler

Florian Ruker

Andreas Grassauer

Georg Maiwald

Michael Bergmann

Andrea Buchacher

Hubert Pehamberger

Renate Predl

Elisabeth Roethl

Annelies Klima

Christine Schmatz

Klaus Wolff

Andrei Egorov

Sabine Brandt

Claudia Ballaun

Wolfgang Ernst

Ales Strancar

Julia Romanova

Bernd Mayer

Oleg Ivanovich Kiselev

Boris Ferko

Peter Palese

Ernst Küchler

Adolfo Garc&iacute;a-Sastre

Johannes Humer

Enami Masayoshi

Andrea Waltenberger

Amy Aspelund

Matjaz Peterka

Elisabeth Gaudernak

Marko Banjac

Ekaterina Romanovskaya-Romanko

Joachim Seipelt

Petra Kramberger

Christian Kittel

Oleg Kiselev

Elisabeth Maurer

The invention relates generally to the field of influenza vaccination, specifically to a two-component vaccine comprising influenza virus strains with native hemagglutinin (HA) and lacking the functional NS gene (delNSI influenza), for use in the vaccination of a subject, wherein a priming composition, comprising one, two or three delNSI influenza virus strains selected from group 1 influenza A virus, group 2 influenza A virus, or group 3, consisting of influenza B virus, is formulated for prime-administration prior to a boosting composition, comprising one, two or three delNSI influenza virus strains of the same group as in the priming composition but differing antigenically in the HA head, formulated for boost-administration. Further, a kit comprising said two-components and its use for preventing influenza virus infection is provided.

Prime-boost influenza vaccine

The present invention provides high growth influenza reassortant virus and high growth influenza reassortant virus vectors comprising amino acid modifications in the PB2, PB1, M1 and/or NS2 proteins which exhibit highly increased growth rates compared to unmodified influenza virus. Further provided are pharmaceutical compositions comprising reassortant virus and viral vectors comprising said modifications and their use for vaccination purposes.

Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2

A process for the purification of influenza virus or derivative thereof requires providing a source of influenza virus or derivative thereof, optionally subjecting the source to a pre-purification step, followed by subjecting the source to at least one chromatographic step on chromatographic material selected from the group consisting of porous particles having mean pore sizes of at least 20 nm, perfusion particles, gel-in-a-shell particles, tentacle like particles, membrane adsorbers, and monoliths, and collecting fractions eluted from the chromatographic material that contain the influenza virus or derivative thereof, excluding sulfuric ester of cellulose or cross-linked polysaccharides.

Method for influenza virus purification

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.

Influenza virus vector for virotherapy

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS 1 protein, wherein said vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing said influenza virus vector, its use for the treatment of cancer patients and methods for producing said influenza virus vaccine.

The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising the modified influenza virus is provided and its use for prevention of influenza vaccination.

Influenza virus

The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided.

Replication deficient influenza virus for the expression of heterologous sequences

The present invention provides a method for generating negative-strand, segmented RNA viruses using linear expression constructs in the presence of helper virus.

Method for generation of RNA virus

The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.

The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.

High growth reassortant influenza A virus

The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.

Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein

Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. 'Fragments' according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.

Polynucleotide fragments of an infectious human endogenous retrovirus

Growing community of inventors

Vienna, Austria

Thomas Muster